NasdaqGS - Delayed Quote USD

bluebird bio, Inc. (BLUE)

0.9228 +0.0103 (+1.13%)
At close: 4:00 PM EDT
0.9400 +0.02 (+1.86%)
After hours: 6:41 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Andrew Obenshain President, CEO & Director 1.04M -- 1974
Mr. Thomas J. Klima Chief Commercial Officer & COO 654.97k -- 1972
Mr. Richard A. Colvin M.D., Ph.D. Chief Medical Officer 696.24k -- 1966
Mr. Christopher Krawtschuk CPA CFO, Principal Accounting Officer & Treasurer -- -- 1974
Mr. Joseph D. Vittiglio Esq., J.D. Chief Legal & Business Officer and Secretary -- -- 1972
Jess Rowlands Head of Corporate Communications -- -- --
Ms. Andrea Walton Chief People Officer -- -- --
Mr. Kasra Kasraian Senior Vice President of Technical Development & Operations -- -- --
Mr. Scott Shoemaker Senior Vice President of Quality -- -- --
Ms. Sarah Alspach Senior Vice President of External Affairs -- -- --

bluebird bio, Inc.

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300 https://www.bluebirdbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
323

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Corporate Governance

bluebird bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 5; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
bluebird bio, Inc. Earnings Call

Related Tickers

TSVT 2seventy bio, Inc.
4.2550
-0.82%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
EDIT Editas Medicine, Inc.
5.32
+1.92%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
 
NVAX Novavax, Inc.
4.0900
+3.54%
 
IBRX ImmunityBio, Inc.
7.35
+43.84%
 
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%